- Seattle Genetics (NASDAQ:SGEN) has agreed to acquire Cascadian Therapeutics (CASC) for $10 per share in cash, more than a 69% premium to yesterday's closing price of $5.90. Total consideration will be ~$614M.
- Cascadian's lead candidate is tyrosine kinase inhibitor tucatinib, highly selective for growth factor receptor HER2 without significantly inhibiting EGFR which causes unwanted side effects.
- SGEN has secured a financing commitment from Barclays and JPMorgan-Chase Bank for $400M. The balance will be funded with cash on hand.
- The transaction should close this quarter.
- Management will host a conference call at 8:30 am ET to discuss the deal.
- Previously: Cascadian's tucatinib an Orphan Drug in U.S. for HER2+ CRC; shares ahead 7% premarket (Sept. 27, 2017)